Zevra Therapeutics Inc
ZVRA
View Detailed Chart
8.870USD
+0.230+2.66%
Close 12/26, 16:00（ET）Quotes delayed by 15 min
498.65MMarket Cap
14.70P/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.66%
5 Days
+6.74%
1 Month
+3.14%
6 Months
-1.44%
Year to Date
+6.35%
1 Year
+5.72%
View Detailed Chart
TradingKey Stock Score of Zevra Therapeutics Inc
Currency: USD Updated: 2025-12-26Key Insights
Zevra Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 56/158 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 22.86.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Zevra Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
8
analysts
Buy
Current Rating
22.857
Target Price
+160.33%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Zevra Therapeutics Inc Highlights
StrengthsRisks
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 132.38% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 23.61M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 23.61M.
Overvalued
The company’s latest PE is 14.70, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 37.37M shares, decreasing 2.78% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 5.30K shares of this stock.
Zevra Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Zevra Therapeutics Inc Info
Zevra Therapeutics, Inc. is a commercial-stage rare disease company combining science, data, and patient need to create transformational therapies for diseases with limited or no treatment options. It has a diverse portfolio of products and product candidates, which includes pre-clinical, clinical, and commercial stage assets. Its active commercial products and development assets include MIPLYFFA, OLPRUVA, Celiprolol, KP1077IH, KP1077N and AZSTARYS. MIPLYFFA (arimoclomol) is its approved therapy for the treatment of Niemann-Pick disease type C (NPC). OLPRUVA (sodium phenylbutyrate) is its treatment for the treatment of certain urea cycle disorders (UCDs). Celiprolol is its investigational clinical candidate for the treatment of Vascular Ehlers-Danlos Syndrome (VEDS). KP1077 is its product candidate intended for the treatment of rare sleep disorders. KP1077N is a clinical development candidate for narcolepsy. AZSTARYS is for the treatment of attention deficit and hyperactivity disorder.
Ticker SymbolZVRA
CompanyZevra Therapeutics Inc
CEOMcfarlane (Neil F)
Websitehttps://zevra.com/
FAQs
What is the current price of Zevra Therapeutics Inc (ZVRA)?
The current price of Zevra Therapeutics Inc (ZVRA) is 8.870.
What is the symbol of Zevra Therapeutics Inc?
The ticker symbol of Zevra Therapeutics Inc is ZVRA.
What is the 52-week high of Zevra Therapeutics Inc?
The 52-week high of Zevra Therapeutics Inc is 13.160.
What is the 52-week low of Zevra Therapeutics Inc?
The 52-week low of Zevra Therapeutics Inc is 6.190.
What is the market capitalization of Zevra Therapeutics Inc?
The market capitalization of Zevra Therapeutics Inc is 498.65M.
What is the net income of Zevra Therapeutics Inc?
The net income of Zevra Therapeutics Inc is -105.51M.
Is Zevra Therapeutics Inc (ZVRA) currently rated as Buy, Hold, or Sell?
According to analysts, Zevra Therapeutics Inc (ZVRA) has an overall rating of Buy, with a price target of 22.857.
What is the Earnings Per Share (EPS TTM) of Zevra Therapeutics Inc (ZVRA)?
The Earnings Per Share (EPS TTM) of Zevra Therapeutics Inc (ZVRA) is 0.603.
Related Instruments
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%Popular Symbols
